糖尿病数字应用技术:EASD与ADA共识报告
欧洲糖尿病研究协会与美国糖尿病协会联合综述糖尿病数字健康应用现状,指出多数健康类应用不受监管,安全性与有效性证据有限。报告识别准确性、临床有效性、培训、互操作性及数据安全等问题,并提出推荐行动。
要点
- 多数健康类移动应用不受监管,除非符合医疗器械定义。
- 糖尿病应用安全性与有效性证据仍有限。
- 需解决准确性、培训、互操作性与数据安全等问题。
核心结论
- 糖尿病数字健康应用需基于最佳安全性与有效性证据,并解决监管与证据不足等问题。
研究设计与样本
- EASD与ADA联合综述糖尿病数字健康技术(仅独立应用,不含胰岛素泵、CGM、自动胰岛素输送系统等受监管医疗器械)及监管实践。
主要发现
- 在美国和欧洲,旨在管理健康与保健的移动应用大多不受监管,除非符合治疗和/或诊断医疗器械定义。
- 国际组织(如IMDRF和WHO)已在数字健康技术分类及整合入医疗器械领域取得进展。
- 糖尿病应用准确性、临床有效性证据不足,且缺乏培训、互操作性与标准化差、数据安全不充分。
临床怎么用
- 临床选择糖尿病应用时应关注其准确性、临床有效性及数据安全性。
- 需推动培训、互操作性与标准化建设以发挥技术潜力。
局限性
- 仅纳入独立糖尿病应用,未涵盖受监管医疗器械中的集成应用。
- 现有证据关于移动健康应用安全性与有效性仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Digital health technology, especially digital and health applications ("apps"), have been developing rapidly to help people manage their diabetes. Numerous health-related apps provided on smartphones and other wireless devices are available to support people with diabetes who need to adopt either lifestyle interventions or medication adjustments in response to glucose-monitoring data. However, regulations and guidelines have not caught up with the burgeoning field to standardize how mobile health apps are reviewed and monitored for patient safety and clinical validity. The available evidence on the safety and effectiveness of mobile health apps, especially for diabetes, remains limited. The European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) have therefore conducted a joint review of the current landscape of available diabetes digital health technology (only stand-alone diabetes apps, as opposed to those that are integral to a regulated medical device, such as insulin pumps, continuous glucose monitoring systems, and automated insulin delivery systems) and practices of regulatory authorities and organizations. We found that, across the U.S. and Europe, mobile apps intended to manage health and wellness are largely unregulated unless they meet the definition of medical devices for therapeutic and/or diagnostic purposes. International organizations, including the International Medical Device Regulators Forum and the World Health Organization, have made strides in classifying different types of digital health technology and integrating digital health technology into the field of medical devices. As the diabetes digital health field continues to develop and become more fully integrated into everyday life, we wish to ensure that it is based on the best evidence for safety and efficacy. As a result, we bring to light several issues that the diabetes community, including regulatory authorities, policy makers, professional organizations, researchers, people with diabetes, and health care professionals, needs to address to ensure that diabetes health technology can meet its full potential. These issues range from inadequate evidence on app accuracy and clinical validity to lack of training provision, poor interoperability and standardization, and insufficient data security. We conclude with a series of recommended actions to resolve some of these shortcomings.
引用
- Fleming GA, Petrie JR, Bergenstal RM, et al. Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care. 2019. PMID: 31806649. doi:10.2337/dci19-0062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。